Kintsugi Therapeutics

kintsugitx.com ↗ ·Barcelona ·Seed

Kintsugi Therapeutics is a Barcelona-based preclinical-stage biopharmaceutical company developing therapies for liver disease that act by regulating endoplasmic reticulum stress. Its lead candidate is a first-in-class endoplasmic reticulum stress inhibitor for non-alcoholic steatohepatitis (NASH), designed to act on several disease mechanisms, including fat accumulation, cell death and inflammation. The company was founded in 2019 by Carmen Herrero and Marc Cusachs and is supported by a scientific and medical advisory board of liver and metabolic disease specialists. Its first €691,000 went to patent protection and animal studies. In November 2021 it raised a further €1 million seed round through the Capital Cell equity crowdfunding platform, with Women Angels for STEAM (WA4STEAM) among the lead investors, to fund regulatory preclinical studies and drug manufacturing ahead of clinical trials. EIT Health has also backed the company.

Founded

2019

Founders

Total funds raised

€986K

SectorsBiotech, Drug Discovery, Liver Disease, NASH Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Carmen Herrero

Co-founder & CEO

Marc Cusachs

Co-founder & COO

Global models 5

Boston Pharmaceuticals

United States · www.bostonpharmaceuticals.com ↗

A privately funded drug developer whose lead asset became a MASH/NASH liver therapy (efimosfermin); it was built to license out or sell its assets to big pharma, which ended in a sale to GSK.

$600MComparable

Terns Pharmaceuticals

United States · www.ternspharma.com ↗

A venture-backed clinical-stage biotech that built a NASH pipeline aimed at several disease mechanisms, with value coming from clinical milestones and partnering rather than product sales.

$180MComparable

Sagimet Biosciences

United States · sagimet.com ↗

A venture-funded biotech developing a first-in-class drug (a FASN inhibitor) that targets fat build-up, inflammation and fibrosis in MASH, much like Kintsugi's multi-mechanism approach.

$170MComparable

Akero Therapeutics

United States · akerotx.com ↗

A VC-backed liver-disease biotech that took a single NASH drug (efruxifermin) through the clinic and was acquired by Novo Nordisk, the exit path a preclinical NASH asset company aims for.

$165MComparable

NorthSea Therapeutics

Netherlands · www.northseatherapeutics.com ↗

A European VC-backed biotech developing a first-in-class drug for MASH and metabolic liver disease, funded round by round to reach clinical proof of concept.

$130MComparable